| Cardiology And Internal Medicine Group Of North Florida P A | |
|
155 Avenue E Apalachicola FL 32320-2069 | |
| (850) 653-4134 | |
| (850) 653-4135 |
| Full Name | Cardiology And Internal Medicine Group Of North Florida P A |
|---|---|
| Speciality | Internal Medicine |
| Location | 155 Avenue E, Apalachicola, Florida |
| Authorized Official Name and Position | Helen Nitsios (OWNER) |
| Authorized Official Contact | 8506534134 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Cardiology And Internal Medicine Group Of North Florida P A 7100 Hollywood Blvd Suite 23 Pembroke Pines FL 33024-7355 Ph: (954) 967-0107 | Cardiology And Internal Medicine Group Of North Florida P A 155 Avenue E Apalachicola FL 32320-2069 Ph: (850) 653-4134 |
| NPI Number | 1245257005 |
|---|---|
| Provider Enumeration Date | 07/17/2006 |
| Last Update Date | 12/05/2022 |
| Medicare PECOS PAC ID | 4587799887 |
|---|---|
| Medicare Enrollment ID | O20100311000660 |
News Archive
Wearable devices have been heralded as one of the next great technological frontiers. They can provide all users, including older ones, with constantly updated medical information by tracking cardiac health, identifying potential illnesses, and serving as emergency alert systems, among other benefits.
The University of Liverpool and the Liverpool School of Tropical Medicine have been awarded £3.54m for a research project that aims to develop a 'personalized health' approach to prevent and treat antimicrobial resistance.
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.
New research has determined that patients in the U.S. with hepatitis C virus (HCV) are twice as likely to not have health insurance coverage compared with those without the disease. In fact researchers found only a third of HCV infected Americans have access to antiviral therapy; the remaining are either uninsured or not candidates for therapy due to treatment contraindications. Details of this study are published in the March issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245257005 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | (* (Not Available)) | Primary |
| Provider Name | Shezad Sanaullah |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1679590426 PECOS PAC ID: 5799751772 Enrollment ID: I20040913001421 |
News Archive
Wearable devices have been heralded as one of the next great technological frontiers. They can provide all users, including older ones, with constantly updated medical information by tracking cardiac health, identifying potential illnesses, and serving as emergency alert systems, among other benefits.
The University of Liverpool and the Liverpool School of Tropical Medicine have been awarded £3.54m for a research project that aims to develop a 'personalized health' approach to prevent and treat antimicrobial resistance.
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.
New research has determined that patients in the U.S. with hepatitis C virus (HCV) are twice as likely to not have health insurance coverage compared with those without the disease. In fact researchers found only a third of HCV infected Americans have access to antiviral therapy; the remaining are either uninsured or not candidates for therapy due to treatment contraindications. Details of this study are published in the March issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).
› Verified 9 days ago
| Provider Name | Helen E Nitsios |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1255358016 PECOS PAC ID: 9830166412 Enrollment ID: I20040913001427 |
News Archive
Wearable devices have been heralded as one of the next great technological frontiers. They can provide all users, including older ones, with constantly updated medical information by tracking cardiac health, identifying potential illnesses, and serving as emergency alert systems, among other benefits.
The University of Liverpool and the Liverpool School of Tropical Medicine have been awarded £3.54m for a research project that aims to develop a 'personalized health' approach to prevent and treat antimicrobial resistance.
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.
New research has determined that patients in the U.S. with hepatitis C virus (HCV) are twice as likely to not have health insurance coverage compared with those without the disease. In fact researchers found only a third of HCV infected Americans have access to antiviral therapy; the remaining are either uninsured or not candidates for therapy due to treatment contraindications. Details of this study are published in the March issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).
› Verified 9 days ago
| Provider Name | Lorie Simmons |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1992723225 PECOS PAC ID: 0941202824 Enrollment ID: I20070206000204 |
News Archive
Wearable devices have been heralded as one of the next great technological frontiers. They can provide all users, including older ones, with constantly updated medical information by tracking cardiac health, identifying potential illnesses, and serving as emergency alert systems, among other benefits.
The University of Liverpool and the Liverpool School of Tropical Medicine have been awarded £3.54m for a research project that aims to develop a 'personalized health' approach to prevent and treat antimicrobial resistance.
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.
New research has determined that patients in the U.S. with hepatitis C virus (HCV) are twice as likely to not have health insurance coverage compared with those without the disease. In fact researchers found only a third of HCV infected Americans have access to antiviral therapy; the remaining are either uninsured or not candidates for therapy due to treatment contraindications. Details of this study are published in the March issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).
› Verified 9 days ago
| Provider Name | Claire T Spence |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255444618 PECOS PAC ID: 9133203482 Enrollment ID: I20201015003194 |
News Archive
Wearable devices have been heralded as one of the next great technological frontiers. They can provide all users, including older ones, with constantly updated medical information by tracking cardiac health, identifying potential illnesses, and serving as emergency alert systems, among other benefits.
The University of Liverpool and the Liverpool School of Tropical Medicine have been awarded £3.54m for a research project that aims to develop a 'personalized health' approach to prevent and treat antimicrobial resistance.
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.
New research has determined that patients in the U.S. with hepatitis C virus (HCV) are twice as likely to not have health insurance coverage compared with those without the disease. In fact researchers found only a third of HCV infected Americans have access to antiviral therapy; the remaining are either uninsured or not candidates for therapy due to treatment contraindications. Details of this study are published in the March issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).
› Verified 9 days ago
News Archive
Wearable devices have been heralded as one of the next great technological frontiers. They can provide all users, including older ones, with constantly updated medical information by tracking cardiac health, identifying potential illnesses, and serving as emergency alert systems, among other benefits.
The University of Liverpool and the Liverpool School of Tropical Medicine have been awarded £3.54m for a research project that aims to develop a 'personalized health' approach to prevent and treat antimicrobial resistance.
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.
New research has determined that patients in the U.S. with hepatitis C virus (HCV) are twice as likely to not have health insurance coverage compared with those without the disease. In fact researchers found only a third of HCV infected Americans have access to antiviral therapy; the remaining are either uninsured or not candidates for therapy due to treatment contraindications. Details of this study are published in the March issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).
› Verified 9 days ago
Franklin Mobile Medicine Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 139 Deer Patch Ln, Apalachicola, FL 32320 Phone: 850-323-0218 Fax: 850-653-9817 | |
Tallahassee Memorial Healthcare Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 137 12th St, Apalachicola, FL 32320 Phone: 850-697-1118 Fax: 850-697-1119 | |
Apalachicola Wellness, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 111 Avenue E, Apalachicola, FL 32320 Phone: 850-653-4545 Fax: 850-653-4949 | |
Franklin County Board Of County Commissioners Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 137 12th St, Apalachicola, FL 32320 Phone: 850-653-1525 Fax: 850-653-1546 | |
Harbor Medical Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 137 12th St, Apalachicola, FL 32320 Phone: 850-653-1212 Fax: 850-653-4805 | |
Weems Medical Center West Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 137 12th Street, Apalachicola, FL 32320 Phone: 850-653-1525 Fax: 850-653-1548 |